ATE236607T1 - Herstellung stellen-spezifischer polyethylenglycol-grf konjugate - Google Patents

Herstellung stellen-spezifischer polyethylenglycol-grf konjugate

Info

Publication number
ATE236607T1
ATE236607T1 AT98959898T AT98959898T ATE236607T1 AT E236607 T1 ATE236607 T1 AT E236607T1 AT 98959898 T AT98959898 T AT 98959898T AT 98959898 T AT98959898 T AT 98959898T AT E236607 T1 ATE236607 T1 AT E236607T1
Authority
AT
Austria
Prior art keywords
grf
conjugates
site
preparation
polyethylene glycol
Prior art date
Application number
AT98959898T
Other languages
English (en)
Inventor
Francesco Maria Veronese
Paolo Caliceti
Oddone Schiavon
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE236607T1 publication Critical patent/ATE236607T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98959898T 1997-12-03 1998-12-01 Herstellung stellen-spezifischer polyethylenglycol-grf konjugate ATE236607T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97121264A EP0922446A1 (de) 1997-12-03 1997-12-03 Lösungsphase Verfahrung zur ortspezifischer Herstellung von GRF-PEG Konjugaten
PCT/EP1998/007748 WO1999027897A1 (en) 1997-12-03 1998-12-01 Site-specific preparation of polyethylene glycol-grf conjugates

Publications (1)

Publication Number Publication Date
ATE236607T1 true ATE236607T1 (de) 2003-04-15

Family

ID=8227732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959898T ATE236607T1 (de) 1997-12-03 1998-12-01 Herstellung stellen-spezifischer polyethylenglycol-grf konjugate

Country Status (30)

Country Link
US (3) US6528485B1 (de)
EP (2) EP0922446A1 (de)
JP (2) JP2001524505A (de)
KR (1) KR100561768B1 (de)
CN (1) CN1149967C (de)
AR (1) AR017780A1 (de)
AT (1) ATE236607T1 (de)
AU (1) AU755285B2 (de)
BG (1) BG64815B1 (de)
BR (1) BR9815159A (de)
CA (1) CA2312004C (de)
DE (1) DE69813291T2 (de)
DK (1) DK1037587T3 (de)
EA (1) EA004269B1 (de)
EE (1) EE200000319A (de)
ES (1) ES2194376T3 (de)
HK (1) HK1034203A1 (de)
HU (1) HUP0100507A3 (de)
IL (2) IL136551A0 (de)
NO (1) NO327238B1 (de)
NZ (1) NZ504570A (de)
PL (1) PL192082B1 (de)
PT (1) PT1037587E (de)
SI (1) SI1037587T1 (de)
SK (1) SK8242000A3 (de)
TR (1) TR200001615T2 (de)
TW (1) TWI254641B (de)
UA (1) UA73716C2 (de)
WO (1) WO1999027897A1 (de)
ZA (1) ZA9811068B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
AU9558901A (en) * 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
EP1234583A1 (de) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
ATE371680T1 (de) * 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
MXPA05002991A (es) * 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
US7662915B2 (en) * 2003-01-18 2010-02-16 Pegsphere Co., Ltd. Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated PEG peptides using the same
US20050058658A1 (en) * 2003-07-15 2005-03-17 Barros Research Institute Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
CA2532250A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
US20050175584A1 (en) * 2004-01-28 2005-08-11 Paciotti Giulio F. Functionalized colloidal metal compositions and methods
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α-干扰素1b的制备方法
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
EP1824988B1 (de) 2004-11-12 2017-04-19 Bayer HealthCare LLC Ortsgerichtete modifizierung von fviii
EP1907067B2 (de) 2005-07-26 2017-06-28 Solvay USA Inc. Polymere mit hängenden poly(alkylenoxy)-substituentengruppen und ihre verwendung in körperpflege-anwendungen
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2018437A2 (de) 2006-05-02 2009-01-28 Allozyne, Inc. Mit nicht-natürlichen aminosäuren substituierte polypeptide
DK2054074T3 (da) * 2006-08-04 2014-11-03 Prolong Pharmaceuticals Llc Modificeret erythropoietin
US20080083154A1 (en) * 2006-10-05 2008-04-10 Timothy M Gregory Bait retention fish hook
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
CA2742710A1 (en) * 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
KR101164453B1 (ko) 2009-03-20 2012-07-11 한미사이언스 주식회사 위치특이적 생리활성 폴리펩타이드 결합체의 제조방법
EP2421547A1 (de) * 2009-04-20 2012-02-29 Theratechnologies Inc. Verwendung von (hexenoyl-trans-3)hgrf(1-44)nh2 und ritonavir in einer kombinationstherapie
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
EP2496248A2 (de) 2009-11-04 2012-09-12 Janssen Pharmaceutica, N.V. Verfahren zur behandlung von herzinsuffizienz mit stresscopin-artigen peptiden
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
WO2012142706A1 (en) 2011-04-21 2012-10-26 Theratechnologies Inc. Growth hormone releasing factor (grf) analogs and uses thereof
EP2715291A4 (de) 2011-05-31 2015-10-21 Airware Inc Rekalibrierung von ab-ndir-gassensoren
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
WO2016187712A1 (en) 2015-05-28 2016-12-01 Institut National De La Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
CN109153712B (zh) * 2016-04-19 2022-09-16 格里芬制药国际公司 Peg化生物活性肽及其用途
CN110317826B (zh) * 2019-05-22 2020-11-10 中国农业大学 调控PvGRF9含量或活性的物质在调控植物茎生长发育中的应用
WO2021133407A1 (en) 2019-12-27 2021-07-01 Compagnie Generale Des Etablissements Michelin Rubber mix with high specific surface area and high structure acetylene carbon black
US11623949B2 (en) 2021-01-28 2023-04-11 Talem Therapeutics Llc Anti-spike glycoprotein antibodies and the therapeutic use thereof
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
ATE136315T1 (de) * 1989-05-27 1996-04-15 Sumitomo Pharma Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine.
ZA914983B (en) * 1990-06-29 1992-03-25 Hoffmann La Roche His-grf-analogs
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
JPH05507939A (ja) * 1991-04-09 1993-11-11 エフ・ホフマン―ラ ロシユ アーゲー 成長ホルモン放出因子の類似体
EP0518295A3 (en) * 1991-06-14 1993-09-01 Millipore Corporation Allyl side chain protection in peptide synthesis
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1997017367A1 (en) * 1995-11-03 1997-05-15 Theratechnologies Inc. Method of grf peptides synthesis

Also Published As

Publication number Publication date
US6528485B1 (en) 2003-03-04
CN1280483A (zh) 2001-01-17
BG104484A (en) 2000-12-29
KR20010032494A (ko) 2001-04-25
AR017780A1 (es) 2001-10-24
WO1999027897A9 (en) 1999-09-30
DE69813291D1 (de) 2003-05-15
EP0922446A1 (de) 1999-06-16
HUP0100507A2 (hu) 2001-08-28
JP2010024245A (ja) 2010-02-04
EP1037587A1 (de) 2000-09-27
NO20002664D0 (no) 2000-05-24
JP2001524505A (ja) 2001-12-04
UA73716C2 (en) 2005-09-15
EP1037587B1 (de) 2003-04-09
JP5431874B2 (ja) 2014-03-05
SK8242000A3 (en) 2001-01-18
SI1037587T1 (en) 2003-08-31
DE69813291T2 (de) 2003-11-13
US6869932B2 (en) 2005-03-22
US20040029794A1 (en) 2004-02-12
HUP0100507A3 (en) 2001-11-28
IL136551A (en) 2008-12-29
NO20002664L (no) 2000-07-13
DK1037587T3 (da) 2003-07-28
TR200001615T2 (tr) 2000-12-21
AU755285B2 (en) 2002-12-05
ES2194376T3 (es) 2003-11-16
EA004269B1 (ru) 2004-02-26
US7317002B2 (en) 2008-01-08
BR9815159A (pt) 2000-10-10
CN1149967C (zh) 2004-05-19
NO327238B1 (no) 2009-05-18
EA200000601A1 (ru) 2000-12-25
CA2312004A1 (en) 1999-06-10
ZA9811068B (en) 1999-06-28
BG64815B1 (bg) 2006-05-31
IL136551A0 (en) 2001-06-14
EE200000319A (et) 2001-08-15
NZ504570A (en) 2003-10-31
WO1999027897A1 (en) 1999-06-10
US20050159353A1 (en) 2005-07-21
TWI254641B (en) 2006-05-11
AU1563399A (en) 1999-06-16
PL192082B1 (pl) 2006-08-31
PT1037587E (pt) 2003-08-29
CA2312004C (en) 2009-05-19
PL341139A1 (en) 2001-03-26
HK1034203A1 (en) 2001-10-19
KR100561768B1 (ko) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE236607T1 (de) Herstellung stellen-spezifischer polyethylenglycol-grf konjugate
DE69833739D1 (de) Kosmetisches Präparat
EE9800123A (et) Stabiilsed lüofiliseeritud ravimvormid
PT973527E (pt) Formulacoes de libertacao prolongada de claritromicina
DE69806055D1 (de) Verbesserte interferon-polymer konjugate
NO20001612D0 (no) Oralt preparat
MA24473A1 (fr) Formulations
PT1283051E (pt) Formulacoes de insulina estaveis
ID19979A (id) Komposisi polietilena berisi
DE69610553T2 (de) Deodorant zusammensetzungen
DE69826138D1 (de) Parfümzusammensetzung
IS5536A (is) Efnablanda fyrir snyrtivörur
BR9710577A (pt) Composi-Æo de xampu
NO982473D0 (no) 5'-Deoksy-cytidinderivater
DE69717034D1 (de) Lippenstift Präparat
DE69834091D1 (de) Kosmetische Zubereitung
DE69930644D1 (de) Herstellung von polyethylen
DE69823490D1 (de) Antitranspirant präparat
BR9605972A (pt) Composição de xampu
DE69813116D1 (de) Thermoplastisch formbare Zusammensetzungen
DE69828708D1 (de) Deodorant-zusammensetzung
DE59807819D1 (de) Duftstoff-enthaltende Zubereitung
BR9708592A (pt) Composição anti-hiv compreendo derivados de imida-zol
NO991430D0 (no) Insektfordrivende formuleringer
ID20194A (id) Penyemprot tegak atau terbalik

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1037587

Country of ref document: EP

EEFA Change of the company name